Table 2 The clinical trials with inhibitors targeting NADPH metabolism in cancer
From: NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications
Target | Inhibitor | Tumor type | Phase | Clinical trial ID | Recruitment status |
|---|---|---|---|---|---|
G6PD | RRx-001 | Malignant solid tumor lymphoma | Phase 1 | NCT02518958 | Completed |
RRx-001 | Lymphomas | Phase 1 | NCT01359982 | Completed | |
RRx-001 | Small cell cancer | Phase 3 | NCT03699956 | Active, not recruiting | |
RRx-001 | Colorectal neoplasms | Phase 2 | NCT02096354 | Active, not recruiting | |
G6PD | DHEA | Breast cancer | Phase 3 | NCT01376349 | Completed |
DHEA | Breast cancer | Phase 3 | NCT01376349 | Completed | |
DHEA | Multiple myeloma and plasma cell neoplasm | Phase 3 | NCT00006219 | Completed | |
G6PD, 6PGD, IDH, GDH | EGCG | Colon cancer | Early Phase 1 | NCT02891538 | Recruiting |
EGCG | Breast neoplasms | Phase 2 | NCT02580279 | Enrolling by invitation | |
EGCG | Lung neoplasms | Phase 2 | NCT02577393 | Enrolling by invitation | |
GDH | Ebselen | Hearing loss/cancer | Phase 1 | NCT01452607 | Completed |
Ebselen | Lung cancer head and neck cancer | Phase 2 | NCT01451853 | Unknown | |
IDHs | AG-881 | Glioma with an IDH1 or IDH2 mutation | Phase 3 | NCT04164901 | Recruiting |
BAY1436032 | Leukemia, myeloid, acute with IDH1 mutations | Phase 1 | NCT03127735 | Completed | |
IDH1 | AG-120 (Tibsovo) | Advanced hematologic malignancies with an IDH1 mutation | Phase 1 | NCT02074839 | Approved |
IDH305 | Advanced malignancies with IDH1 mutations | Phase 1 | NCT02381886 | Active, not recruiting | |
FT-2102 | Tumors with IDH1 mutations including: glioma chondrosarcoma, hepatobiliary tumors | Phase 1/2 | NCT03684811 | Active, not recruiting | |
IDH2 | AG-221 (Enasidenib) | Hematologic neoplasms with an IDH2 mutations | Phase 1/2 | NCT01915498 | Approved |
